AbbVie Strikes an All-Cash Deal AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash transaction worth roughly $10.9 billion. Under the…
April 09, 2026
Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has officially announced a significant technological advancement in its clinical development pipeline. The company is successfully developing a new, brain-penetrating…
March 30, 2026
Connect Biopharma (NASDAQ: CNTB) Shares Spike Following Positive Rademikibart Trial Data
Connect Biopharma Holdings Limited (NASDAQ: CNTB) experienced an 11% surge in its stock price recently. The market responded enthusiastically after the biotechnology company released highly…
November 13, 2025
BrainsWay Gains FDA Clearance for Deep TMS™ as Adjunct Therapy for Adolescents with Major Depressive Disorder
The decision is based on one of the most comprehensive real-world adolescent neuromodulation datasets ever submitted to the agency: tracking 1,120 adolescents treated across 35…
November 13, 2025
Day One Biopharmaceuticals Acquires Mersana Therapeutics to Bolster Oncology Pipeline
Day One Biopharmaceuticals (NASDAQ: DAWN) has entered into a definitive agreement to acquire Mersana Therapeutics, (NASDAQ: MRSN) a clinical-stage biotech known for its antibody-drug conjugate…
October 20, 2025
Kairos Pharma Announces Promising Interim Results for ENV-105 in Advanced Prostate Cancer Trial
Kairos Pharma (NYSE: KAPA) has revealed positive interim efficacy data from its Phase 2 trial of ENV-105 for metastatic castration-resistant prostate cancer (mCRPC). The findings,…
October 20, 2025
CorMedix Inc. Reports Strong Preliminary Q3 2025 Results and Raises Full-Year Revenue Guidance
CorMedix Inc. (Nasdaq: CRMD) has announced its preliminary unaudited financial results for the third quarter of 2025, showcasing robust revenue growth and operational momentum. The…
October 17, 2025
BiomX Announces FDA Feedback Supporting Expanded Development Pathways for BX004 in Cystic Fibrosis
BiomX Inc. (NYSE: PHGE), a clinical-stage company developing natural and engineered bacteriophage therapies, announced progress in addressing regulatory feedback on its BX004 program for cystic…
October 16, 2025
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company dedicated to developing innovative multimodal viral immunotherapies to combat cancer, announced today the appointment of Bali…
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage global biopharmaceutical company, has announced promising results from Arm A1 of its Phase 2 EDGE-Gastric study. The study…
October 08, 2025
Vanda Pharmaceuticals Joins Monumental Sports & Entertainment as Founding Partner for New Downtown Arena
Monumental Sports & Entertainment (MSE) has announced a groundbreaking partnership with Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a globally recognized biopharmaceutical company headquartered in Washington, D.C….
October 02, 2025
Quantum BioPharma Advances Multiple Sclerosis Drug Development with Key Study Reports
Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, has announced a significant milestone in the development…